News headlines about Miragen Therapeutics (NASDAQ:MGEN) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Miragen Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 44.6758920916078 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- EPS for Miragen Therapeutics, Inc. (MGEN) Expected At $-0.32 – NMSU Hеrаld (nmsuherald.com)
- Broadcom, Qualcomm, Miragen Therapeutics, Savara Inc and more – AFTER HOURS – Proactive Investors UK (proactiveinvestors.co.uk)
- Miragen Therapeutics (MGEN) Research Coverage Started at Evercore ISI (americanbankingnews.com)
- UPDATE: Evercore ISI Starts miRagen Therapeutics (MGEN) at … – StreetInsider.com (streetinsider.com)
- Miragen Therapeutics, Inc. (MGEN) price is -33.49% below its 200-SMA – The Stocks News (press release) (thestocksnews.com)
Several analysts have commented on MGEN shares. Cann reaffirmed a “buy” rating and issued a $13.00 target price on shares of Miragen Therapeutics in a research note on Friday, February 2nd. Chardan Capital reiterated a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a report on Thursday, January 18th. B. Riley started coverage on shares of Miragen Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $15.50 price target on the stock. Finally, Wedbush reiterated a “buy” rating and issued a $19.00 price target on shares of Miragen Therapeutics in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $16.82.
In other news, insider Adam Scott Levy acquired 9,090 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were purchased at an average price of $5.50 per share, for a total transaction of $49,995.00. Following the acquisition, the insider now directly owns 10,540 shares of the company’s stock, valued at approximately $57,970. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas E. Hughes sold 12,000 shares of the business’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $8.00, for a total transaction of $96,000.00. The disclosure for this sale can be found here. Insiders own 44.40% of the company’s stock.
WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/14/miragen-therapeutics-mgen-given-daily-news-sentiment-score-of-0-06/2029448.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.